About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research conducted in our group is geared toward elucidating the cause and molecular mechanisms of neurodegeneration in Parkinson's disease (PD), a disabling, currently incurable common neurodegenerative disorder. To this end, we perform clinical and pre-clinical translational research in both PD patients and in human-relevant experimental in vitro and in vivo PD-related models.
Elucidating the molecular mechanisms underlying neurodegeneration in PD should allow to:
IP: Marta Martínez Vicente Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Pablo Castillo Sánchez Funding agency: Fundació "La Caixa" Funding: 249950 Reference: HR22-00602 Duration: 01/11/2022 - 31/10/2025
IP: Sara Marsal Barril Collaborators: Antonio Julia Cano, Javier Hoyo Pérez, Elena Granell Pallares, Adria Aterido Ballonga, Montse Sender Beleta Funding agency: EUROPEAN COMMISSION Funding: 1079085 Reference: DOCTIS_H2020_SC1-BHC2019 Duration: 01/01/2020 - 31/12/2025
IP: Marta Martínez Vicente Collaborators: José Antonio Arranz Amo, Jorge Hernández Vara, Eddie Pradas Gracia, Guillem Pintos Morell, Clara Carnicer Cáceres, Carles Lorenzo Bosquet, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Daniela Samaniego Toro, Laura Castillo Ribelles, Daniela Samaniego Toro Funding agency: Instituto de Salud Carlos III Funding: 245932.5 Reference: PI20/00728 Duration: 01/01/2021 - 30/06/2025
IP: Miquel Vila Bover Collaborators: Sex-based modulation of neuromelanin-linked Parkinson’s disease pathology Funding agency: Michael J. Fox Foundation Funding: 163538.22 Reference: SEX_NEUROMELANINE_MJFF2020 Duration: 01/02/2021 - 31/12/2024
PMID: 37075138 Journal: PERFUSION-UK Year: 2023 Reference: Perfusion. 2023 Apr 19:2676591231170480. doi: 10.1177/02676591231170480. Impact factor: Publication type: Paper in international publication Authors: Argudo, Eduard; Barrabes, Jose A; Bonilla, Camilo; Chiscano, Luis; De la Iglesia, Ana; Diaz, Maria Angeles; Ferreira-Gonzalez, Ignacio; Ferrer, Ricard; Font, Marta; Gabaldon, Alejandra et al. DOI: 10.1177/02676591231170480
PMID: 37844866 Journal: NEUROPHARMACOLOGY Year: 2023 Reference: Neuropharmacology. 2023 Oct 14:109759. doi: 10.1016/j.neuropharm.2023.109759. Impact factor: Publication type: Paper in international publication Authors: Benlloch, Luis E; Carcel, Paula; Cedena Romero, Maria Teresa; Crucitti, Davide; De Miguel Sanchez, Carlos; Del Orbe Barreto, Rafael Andres; Diaz Varela, Nicolas A; Diaz-Beya, Marina; Diez-Campelo, Maria; Fernandez-Gonzalez, Pol et al. DOI: 10.1016/j.neuropharm.2023.109759
PMID: 37846799 Journal: CANCER Year: 2023 Reference: Cancer. 2023 Oct 17. doi: 10.1002/cncr.35061. Impact factor: Publication type: Paper in international publication Authors: Bisogno, Gianni; Bouhamama, Amine; Brennan, Bernadette; Brisse, Herve J; Cardoen, Liesbeth; Coma, Ana; Coppadoro, Beatrice; Di Paolo, Pier Luigi; Fayard, Cindy; Fernandez-Gonzalez, Pol et al. DOI: 10.1002/cncr.35061
PMID: 37922009 Journal: INTENSIVE CARE MEDICINE Year: 2023 Reference: Intensive Care Med. 2023 Nov 3. doi: 10.1007/s00134-023-07251-0. Impact factor: Publication type: Editorail in international publication Authors: Ambale-Venkatesh, Bharath; Belohlavek, Jan; Bluemke, David A; Fujii, Tomoki; Gomes, Antoinette S; Hundley, W Gregory; Jung, Christian; Lima, Joao A C; Noda, Chikara; Redhueil, Alban et al. DOI: 10.1007/s00134-023-07251-0
On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.
Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.
This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.
Vall d'Hebron Iniciativa per al Parkinson (VHIP) is a research project aimed at the development of biochemical markers for the early detection of Parkinson's disease. This study is carried out in people at high risk of having this disease, because they carry genetic mutations that predispose to the development of Parkinson's or because they present non-motor symptoms that manifest themselves years before motor symptoms.
